Tabsh K, Rizzo W B, Holbrook K, Theroux N
Department of Obstetrics and Gynecology, University of California, Los Angeles School of Medicine.
Obstet Gynecol. 1993 Oct;82(4 Pt 2 Suppl):700-3.
Sjögren-Larsson syndrome is an autosomal recessive disease with sequelae including ichthyosis, mental retardation, and spasticity. Although fetal skin biopsy has permitted prenatal diagnosis of Sjögren-Larsson syndrome in the late second trimester, it is accompanied by substantial risks, including fetal loss, premature labor, and detection at a gestational age close to the legal limit for pregnancy termination in most states. A new technique involving biochemical assay of cultured amniocytes for reduced levels of fatty alcohol:oxidized nicotinamide-adenine dinucleotide (NAD+)-oxidoreductase may allow earlier and less invasive detection of Sjögren-Larsson syndrome.
A 38-year-old Lebanese woman, gravida 6, para 3, presented for prenatal diagnosis of Sjögren-Larsson syndrome following a history of two children born with the disease. At 19 weeks' gestation, multiple fetal skin biopsies were obtained by ultrasound-guided transabdominal percutaneous insertion of biopsy forceps. Histologic examination of the specimen revealed no evidence of Sjögren-Larsson syndrome. However, assay of fatty alcohol:NAD(+)-oxidoreductase in cultured amniocytes obtained at fetal skin biopsy showed a profound enzymatic deficiency. Additional fetal skin biopsies were obtained at 23.5 weeks' gestation, and histologic examination was positive for Sjögren-Larsson syndrome. The patient elected to terminate the pregnancy, and a subsequent autopsy on the fetus confirmed Sjögren-Larsson syndrome.
This case demonstrates the limitations of histologic examination of fetal skin specimens for the diagnosis of Sjögren-Larsson syndrome and indicates the potential value of biochemical detection from fetal amniocytes. This new technique may allow earlier diagnosis of Sjögren-Larsson syndrome, is less invasive, and may be less psychologically traumatic for the patient if she elects to terminate the pregnancy.
舍格伦 - 拉松综合征是一种常染色体隐性疾病,其后遗症包括鱼鳞病、智力迟钝和痉挛。尽管胎儿皮肤活检已能在孕中期晚期对舍格伦 - 拉松综合征进行产前诊断,但它伴随着重大风险,包括胎儿丢失、早产以及在大多数州接近法定妊娠终止期限的孕周被检测出。一种涉及对培养的羊膜细胞进行生化检测以测定脂肪醇:氧化型烟酰胺腺嘌呤二核苷酸(NAD +)氧化还原酶水平降低的新技术,可能允许更早且侵入性更小地检测舍格伦 - 拉松综合征。
一名38岁的黎巴嫩女性,孕6产3,因有两个患该病的孩子出生史前来进行舍格伦 - 拉松综合征的产前诊断。妊娠19周时,通过超声引导经腹经皮插入活检钳获取了多个胎儿皮肤活检样本。标本的组织学检查未发现舍格伦 - 拉松综合征的迹象。然而,对胎儿皮肤活检获取的培养羊膜细胞中的脂肪醇:NAD(+)氧化还原酶进行检测显示存在严重的酶缺乏。在妊娠23.5周时又获取了额外的胎儿皮肤活检样本,组织学检查显示舍格伦 - 拉松综合征呈阳性。患者选择终止妊娠,随后对胎儿进行的尸检证实为舍格伦 - 拉松综合征。
该病例证明了胎儿皮肤标本组织学检查在诊断舍格伦 - 拉松综合征方面的局限性,并表明从胎儿羊膜细胞进行生化检测的潜在价值。这项新技术可能允许更早诊断舍格伦 - 拉松综合征,侵入性更小,并且如果患者选择终止妊娠,对其心理创伤可能更小。